Harrow (HROW) Stock: Buy, Sell, or Hold?
$29.37
-0.99 (-3.26%)
▼
5d:
+2.16%
30d:
+4.0%
90d:
-24.44%
QUANTITATIVE VERDICT
BUY
MODERATE Confidence (57%)
Quality Score
53/100
Position
EXTENDED
30-Day Fair Range
$27.54 – $29.96
Position: EXTENDED
Forward P/E & Valuation
11.0x
CHEAP
vs 16.4x historical avg
Wall Street Target
$62.63
+113.2% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$25.76 / $33.68
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
💡 BUY OPPORTUNITY: HROW shows positive signals but monitor for confirmation. Market pricing in 12.4% decline. Moderate conviction.
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Nov 11, 2026 at $29.40 · last confirmed Nov 11, 2026
Strength: 6.0/10
Get Alerted When HROW Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$85.06
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$52.81
44.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HROW is currently trading at $29.37, which is considered extended relative to its 30-day fair value range of $27.54 to $29.96. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.0) compared to its historical average (16.4). Remarkably, the market is currently pricing in an annual earnings decline of 12.4% over the next few years. This pessimistic expectation contrasts with the company's recent 810.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, HROW is in a strong downtrend. Immediate support is located at $25.76, while resistance sits at $33.68. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: HROW scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $62.62 (+113.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HROW is in a strong downtrend. Immediate support is located at $25.76, while resistance sits at $33.68. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: HROW scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $62.62 (+113.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$27.54 -
$29.96
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Trading Range & Key Levels
30-Day Trading Range
$27.54 -
$29.96
Current vs Trading Range
EXTENDED
Support Level
$25.76
Resistance Level
$33.68
Current Trend
Strong Downtrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 113.2% below Wall St target ($62.62)
- BULLISH: Bottoming setup score 68/100 — corrected, stabilizing, and turning up
Fundamental Context
Forward P/E (Next Year Est.)
11.03
Wall Street Target
$62.63
(+113.2%)
Revenue Growth (YoY)
38.6%
Earnings Growth (YoY)
810.4%
Profit Margin
-9.4%
Valuation Discount vs History
-12.4% cheaper
PE vs Historical
11.0 vs 16.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-12.4%
(market-implied from PE analysis)
1-Year Target
$26.43
(-10%)
2-Year Target
$23.79
(-19%)
3-Year Target
$21.41
(-27%)
3-Yr Target (if PE normalizes)
(PE: 11→16)
$31.84
(+8%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 6558.2%)
$178.51
(+508%)
Base:
(SPY PE: 11.0, Growth: 6558.2%)
$99.12
(+238%)
Bear:
(PE: 9.4, Growth: 6558.2%)
$84.26
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.0 to 16.4
Stabilization Target:
$43.68
(+48.7%)
PE Expansion Potential:
+48.7%
Share HROW Analysis
Share this live HROW analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (HROW)
Bullish
9 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
8 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
HROW reported record Q3 revenue, reaffirmed full-year revenue guidance, but sharply reduced adjusted EBITDA outlook due to lower-than-expected margins and accelerated spending.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 7:18 PM ET
Data refreshes hourly during market hours. Next update: 8:18 PM
Data refreshes hourly during market hours. Next update: 8:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HROW showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 33 SELL |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$687 | 52 HOLD |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
15 analysts |
$49 | 34 SELL |
Advanced HROW Option Strategies
Professional options setups generated by AI based on today's HROW price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive HROW Research Pages
